Deerfield Provides $125 million Debt Financing to Tris Pharma

Deerfield provides growth capital financing to Tris Pharma

New York, New York – October 4, 2018 – Deerfield announced today it provided $125 million to refinance existing debt and provide growth capital to Tris Pharma, Inc. This financing allows Tris to expand its branded pharmaceutical portfolio with a particular focus on Attention Deficit Hyperactivity Disorder (ADHD), launch and promote new products and continue development of its drug development platform.

In addition to the financing, Deerfield and Tris plan to enter into a product development agreement to leverage Tris’ proprietary drug delivery technology.

“Deerfield has partnered with Tris to provide a solution to address all our capital needs in a manner that allows Tris to fully focus on rapidly growing our branded ADHD business and expanding our R&D commitment,” stated Ketan Mehta, president and chief executive officer of Tris. “Additionally, by leveraging our drug delivery technology in partnership with Deerfield, we benefit from Deerfield’s expertise and capabilities.”

“This financing provides a solid foundation upon which Tris can promote and launch existing and new products, and we look forward to its success. Furthermore, Deerfield is delighted to collaborate with Tris’ strong management team as a long-term partner, and to develop new drugs that can be delivered through the company’s proprietary technology” stated Jim Flynn, Deerfield’s managing partner.

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit


Deerfield Management
Company Karen Heidelberger, 212-551-1600
[email protected]